Lee, S., Lu, S., Hayashi, H., Felip, E., Spira, A. I., Girard, N., . . . Cho, B. C. (2025). Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: A randomized, double-blind, exploratory analysis from MARIPOSA. Journal of thoracic oncology, 20(11), . https://doi.org/10.1016/j.jtho.2025.06.030
Chicago-Zitierstil (17. Ausg.)Lee, Se-Hoon, et al. "Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis from MARIPOSA." Journal of Thoracic Oncology 20, no. 11 (2025). https://doi.org/10.1016/j.jtho.2025.06.030.
MLA-Zitierstil (9. Ausg.)Lee, Se-Hoon, et al. "Lazertinib Versus Osimertinib in Previously Untreated EGFR-mutant Advanced NSCLC: A Randomized, Double-blind, Exploratory Analysis from MARIPOSA." Journal of Thoracic Oncology, vol. 20, no. 11, 2025, https://doi.org/10.1016/j.jtho.2025.06.030.